Literature DB >> 2793374

Phase I study of 4'-deoxydoxorubicin (esorubicin) in children with malignant solid tumors.

C B Pratt1, E C Douglass, W H Meyer, F A Hayes, M E Horowitz, E I Thompson, L Avery.   

Abstract

4'-Deoxydoxorubicin was given to 15 patients with drug-resistant pediatric malignant solid tumors with the objectives of determining the maximum tolerated dosage and dose-limiting toxicity. Maximum tolerated dosage was 36 mg/m2 given IV once every 3 weeks. Dose limiting toxicity was myelosuppression, which was severe and prolonged. Therapeutic benefits were not observed for these patients.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2793374     DOI： 10.1007/bf00170859

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  6 in total

1.  Synthesis and antitumor activity of 4'-deoxydaunorubicin and 4'-deoxyadriamycin.

Authors:  F Arcamone; S Penco; S Redaelli; S Hanessian
Journal:  J Med Chem       Date:  1976-12       Impact factor: 7.446

Review 2.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  The interaction of adriamycin and adriamycin analogues with nucleic acids in the B and A conformations.

Authors:  T W Plumbridge; J R Brown
Journal:  Biochim Biophys Acta       Date:  1979-06-20

4.  Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.

Authors:  G F Stanton; V Raymond; R E Wittes; P Schulman; D Budman; R Baratz; L Williams; G R Petroni; N L Geller; C Hancock
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

5.  New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse.

Authors:  F C Giuliani; N O Kaplan
Journal:  Cancer Res       Date:  1980-12       Impact factor: 12.701

6.  Phase I study with 4'-deoxydoxorubicin.

Authors:  L Ferrari; A Rossi; C Brambilla; V Bonfante; F Villani; F Crippa; G Bonadonna
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.